Drug Profile
GL 2021
Latest Information Update: 25 Nov 1995
Price :
$50
*
At a glance
- Originator Genelabs Technologies
- Class Antithrombotics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Thrombosis
Most Recent Events
- 25 Nov 1995 Discontinued-Preclinical for Thrombosis in USA (Unknown route)